GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (FRA:4TO) » Definitions » Stock Based Compensation

Mainz Biomed NV (FRA:4TO) Stock Based Compensation : €1.77 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Stock Based Compensation?

Mainz Biomed NV's Stock Based Compensation for the three months ended in Dec. 2024 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was €1.77 Mil.


Mainz Biomed NV Stock Based Compensation Historical Data

The historical data trend for Mainz Biomed NV's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Stock Based Compensation Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial - 5.69 9.27 3.67 1.09

Mainz Biomed NV Quarterly Data
Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 1.02 0.75 - -

Mainz Biomed NV Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.77 Mil.


Mainz Biomed NV Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Mainz Biomed NV Business Description

Traded in Other Exchanges
Address
Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed NV Headlines

No Headlines